Leukemia

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia

By

Results of a triple-blind study demonstrate effectiveness of zinc sulfate in preventing chemotherapy-induced mucositis or reducing its incidence and severity in patients with leukemia receiving chemotherapy.

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment. 2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing []

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

Tisagenlecleucel Produces Durable Remissions in Pediatric, Young Adult B-cell ALL

By

A previous single-site trial showed that patients with R/R B-cell ALL treated with tisagenlecleucel achieved high complete remission rates. In this study, investigators report on results after the scope of the study was expanded.

Acute lymphoblastic leukemia disease burden associated with safety and efficacy of CD19-CAR therapy

1. Patients with a higher disease burden of acute lymphoblastic leukemia (ALL) treated with CD19-specific chimeric antigen receptor (CAR) T cell therapy experienced greater incidences of cytotoxic release syndrome and neurotoxicity compared to low disease burden patients. 2. Patients with high disease burden had shorter overall survival times compared to low disease burden patients. Evidence []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL

By

Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

Imatinib an Effective Front-line Therapy for Patients With Pediatric CML

By

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

Venetoclax Effective in Ibrutinib-Failed Chronic Lymphocytic Leukemia

By

The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

By

Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.

More Communication, Support Needed to Manage Symptom Burden in CML

More Communication, Support Needed to Manage Symptom Burden in CML

By

Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.

MDS, AML a Risk With PARP Inhibitors in <i>BRCA</i> Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

By

What is the concern behind PARP inhibitors and leukemia?

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

By

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

By

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

Oncologists, Patients Have Different Views on AML Treatment Outcomes, Prognosis

By

Comparison study via questionnaires assessed patients' and oncologists' views on likelihood of dying as a result of treatment shortly after beginning intensive or nonintensive chemotherapy for AML, and their views on prognosis 1 month later.

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

By

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

Complications and Management of Coagulation Disorders in Leukemia Patients

Complications and Management of Coagulation Disorders in Leukemia Patients

[Blood and Lymphatic Cancer: Targets and Therapy] Investigators conduct 4 case studies that illustrate a range of coagulation disorders that can develop in patients with leukemia to elucidate the rationale and process of specific treatment options.

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Lenalidomide Maintenance Therapy Reduced Risk of Progression in CLL

Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

By

Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

By

The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

FDA Grants Approval to Idhifa for Some Patients With Acute Myeloid Leukemia

For adults with relapsed or refractory AML who have an IDH2 genetic mutation

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

By

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

By

Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs